AFYA Afya

Afya Limited Announces Medical Harbour Acquisition

Afya Limited Announces Medical Harbour Acquisition

NOVA LIMA, Brazil and MINAS GERAIS, Brazil, April 08, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA) today announced the acquisition of 100% of the total share capital of Medical Harbour, through its wholly-owned subsidiary Afya Participações S.A.

Medical Harbour offers Educational Health and Medical Imaging Solutions through an interactive platform for anatomical study, 3D virtual dissection and analysis of medical images, which allow the exploration, and knowledge of human anatomy with digital resources.

  • Educational Health Solutions: Athena Hub specialized in anatomy was created to support dynamic teaching and allow physicians, teachers and students to interact and manipulate a real human body on a digital platform. Considering the high prices, restriction policies and difficulty on maintaining a human body for anatomy classes, Athena Hub is a perfect solution allowing students to interact with a digital human body instead of the aged and degenerate bodies for educational purposes, in any devices with a Windows 10 system, without the need of VR glasses. The solution count with Virtual Body, anatomy modules, and real exam analysis with photorealistic rendering. Over 50 universities in Brazil are using the solution.
  • Medical Imaging Solutions: Athena DICOM and MH Cloud specialized in medical imaging with a range of products that simplifies Radiology and Teleradiology. Allow physicians to visualize, manipulate, share and store medical imaging with the certification of ANVISA (Brazilian Health Agency). The solution has over 24,000 downloads in 180 countries.

“We are excited to add Medical Harbour to our portfolio. This acquisition enables Afya to start providing a high quality solution to study the human body, allowing efficient classes and remote lab sessions with greater student acceptance and scalability. Additionally, we will be able to distribute Medical Harbour solutions to all of Afya’s ecosystem, creating B2C and B2B growth opportunities,” said Virgílio Gibbon, Afya’s CEO.

The aggregate purchase price is R$ 5 million (Enterprise Value) of which 100% paid in cash as the date hereof, equivalent to 3.3x gross revenue expected in 2021. An earn-out of R$ 9 million can be paid related to product development goals for 2021/2022 and revenue achievements for 2023.

More information available on: /acquisitions

About Afya

Afya is a leading medical education group in Brazil based on number of medical school seats, delivering an end-to-end physician-centric ecosystem that serves and empowers students and physicians to transform their ambitions into rewarding lifelong experiences from the moment they join us as medical students through their medical residency preparation, graduation program, continuing medical education activities and their daily practices with digital products.

Contact: Investor Relations:



EN
08/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Afya

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommen...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Breakouts Proliferate; Bullish Outlook Intact The S&P 500, Nasdaq 100, and DJI are breaking out to new all-time highs following 3-week consolidations, while the small-cap Russell 2000 (IWM), mid-cap S&P 400 (IJH), Vanguard Extended Market ETF (VXF), and countless other Sectors/industries are breaking out from 3-week bullish falling wedge/flag patterns. This is classic bull market behavior. Considering market dynamics remain healthy, this is all evidence that supports our ongoing bullish outlook...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Year-End Rally to Continue? The broad equity market has been on an absolute tear since we discussed in our 10/31/23 Compass how risk/reward favored buyers as key supports were being tested, including 4165 on the S&P 500, $162-$163 on the Russell 2000 (IWM), and $350 on the Nasdaq 100 (QQQ). Furthermore, we discussed in our 11/7/23 Compass our belief that this was more than just another counter-trend rally, and that it is likely the start of a significant year-end rally. We also reiterated our b...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Bullish Breadth Divergences Persist The S&P 500 is just below 4165-4200 support, and the Nasdaq 100 (QQQ) is just below $350-$355 support. Given they were only 1%-1.5% below these supports at last week's lows, we cannot call them "decisive" breakdowns quite yet. Regardless, these levels are now resistance (in addition to the 200-day MA on SPX), and they are important lines-in-the-sand moving forward. We cannot be bullish if the SPX and QQQ are below the aforementioned levels, but it would be bu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch